Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.41 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.40 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916977 | 0.86 | HRH2 (0.47) | HRH3ALDH1A1KMT2AMAPTHRH2 | |
| SCHEMBL4186059 | 0.86 | HRH2 (0.47) | HRH3ALDH1A1KMT2AMAPTHRH2 | |
| SCHEMBL2913102 | 0.86 | HRH2 (0.47) | HRH3ALDH1A1KMT2AMAPTHRH2 | |
| SCHEMBL2916182 | 0.86 | HRH2 (0.47) | HRH3ALDH1A1KMT2AMAPTHRH2 | |
| SCHEMBL10622903 | 0.86 | HRH2 (0.47) | HRH3ALDH1A1KMT2AMAPTHRH2 | |
| SCHEMBL5217908 | 0.84 | — | — | |
| SCHEMBL8963848 | 0.82 | TBXAS1 (0.49) | AOC1ESR1CYP19A1HRH3TP53 | |
| SCHEMBL23704534 | 0.81 | AOC1 (0.43) | AOC1ESR1CYP19A1HRH3TP53 | |
| SCHEMBL5269768 | 0.81 | TSHR (0.50) | AOC1ESR1CYP19A1HRH3TP53 | |
| SCHEMBL10625908 | 0.78 | SLC6A5 (0.54) | CYP19A1ALDH1A1CYP3A4TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107106694-B | Process for the preparation of butyric esters of hyaluronic acid sodium salt in water | 西格亚有限公司 | 2020-09-22 | — | — | CN | claimed |
| US-10618982-B2 | Process in water for the preparation of butyric esters of hyaluronic acid sodium salt | BMG PHARMA S.P.A. (IT) | 2020-04-14 | — | — | US | claimed |
| EP-3245233-B1 | PROCESS IN WATER FOR THE PREPARATION OF BUTYRIC ESTERS OF HYALURONIC ACID SODIUM SALT | BMG PHARMA S P A (IT) | 2018-10-24 | — | — | EP | claimed |
| US-20180273648-A1 | PROCESS IN WATER FOR THE PREPARATION OF BUTYRIC ESTERS OF HYALURONIC ACID SODIUM SALT | SIGEA S.R.L. (IT) | 2018-09-27 | — | — | US | claimed |
| EP-3245233-A1 | PROCESS IN WATER FOR THE PREPARATION OF BUTYRIC ESTERS OF HYALURONIC ACID SODIUM SALT | Sigea S.R.L. (IT) | 2017-11-22 | — | — | EP | claimed |
| WO-2016113192-A1 | PROCESS IN WATER FOR THE PREPARATION OF BUTYRIC ESTERS OF HYALURONIC ACID SODIUM SALT | SIGEA S.R.L. (IT) | 2016-07-21 | — | — | WO | claimed |
| US-12624129-B2 | Crosslinked butyrate or butyrate-formate derivatives of hyaluronic acid and the crosslinking thereof | BMG PHARMA S.P.A. (IT) | 2026-05-12 | — | — | US | disclosed |
| US-20220411541-A1 | CROSSLINKED BUTYRATE OR BUTYRATE-FORMATE DERIVATIVES OF HYALURONIC ACID AND THE CROSSLINKING THEREOF | BMG PHARMA S.P.A. (IT) | 2022-12-29 | — | — | US | disclosed |
| EP-4061314-A1 | CROSSLINKED BUTYRATE OR BUTYRATE-FORMATE DERIVATIVES OF HYALURONIC ACID AND THE CROSSLINKING PROCESS THEREOF | BMG Pharma S.p.A. (IT) | 2022-09-28 | — | — | EP | disclosed |
| WO-2021099977-A1 | CROSSLINKED BUTYRATE OR BUTYRATE-FORMATE DERIVATIVES OF HYALURONIC ACID AND THE CROSSLINKING PROCESS THEREOF | BMG PHARMA S.P.A. (IT) | 2021-05-27 | — | — | WO | disclosed |
| CN-107106694-B | Process for the preparation of butyric esters of hyaluronic acid sodium salt in water | 西格亚有限公司 | 2020-09-22 | — | — | CN | disclosed |
| CN-107106694-B | Process for the preparation of butyric esters of hyaluronic acid sodium salt in water | 西格亚有限公司 | 2020-09-22 | — | — | CN | disclosed |
| US-10618982-B2 | Process in water for the preparation of butyric esters of hyaluronic acid sodium salt | BMG PHARMA S.P.A. (IT) | 2020-04-14 | — | — | US | disclosed |
| WO-2016113192-A1 | PROCESS IN WATER FOR THE PREPARATION OF BUTYRIC ESTERS OF HYALURONIC ACID SODIUM SALT | SIGEA S.R.L. (IT) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016113192-A1 | PROCESS IN WATER FOR THE PREPARATION OF BUTYRIC ESTERS OF HYALURONIC ACID SODIUM SALT | SIGEA S.R.L. (IT) | 2016-07-21 | — | — | WO | disclosed |
| EP-1450795-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003047576-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0603309-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
| US-4717512-A | Preparation of acylated glycerophosphocholines and glycerophosphoethanolamines | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1988-01-05 | — | — | US | disclosed |
| US-4622180-A | Derivatives of glycerophosphocholine and glycerophosphoethanolamine, their preparation and their use | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1986-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624129-B2 | Crosslinked butyrate or butyrate-formate derivatives of hyaluronic acid and the crosslinking thereof | CD44, MUC1, FGB | AOC1 3609/4885ESR1 4610/4885CYP19A1 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.